Drugs / DC1 Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00970203 | Sep 2009 → Oct 2018 | prostate cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03384914 Comparator | Feb 2018 → Dec 2025 overdue | HER2 positive breast carcinoma, female breast carcinoma, male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC1 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00970203 ↗ |
| Modality | Cell therapy | “alpha-type-1-polarized dendritic cells (DC1)” NCT00970203 ↗ |
| Route | Other | “via intranodal injection” NCT03384914 ↗ |